mTORC1 maintains the tumorigenicity of SSEA-4(+) high-grade osteosarcoma

Sci Rep. 2015 Apr 8:5:9604. doi: 10.1038/srep09604.

Abstract

Inactivation of p53 and/or Rb pathways restrains osteoblasts from cell-cycle exit and terminal differentiation, which underpins osteosarcoma formation coupled with dedifferentiation. Recently, the level of p-S6K was shown to independently predict the prognosis for osteosarcomas, while the reason behind this is not understood. Here we show that in certain high-grade osteosarcomas, immature SSEA-4(+) tumor cells represent a subset of tumor-initiating cells (TICs) whose pool size is maintained by mTORC1 activity. mTORC1 supports not only SSEA-4(+) cell self-renewal through S6K but also the regeneration of SSEA-4(+) TICs by SSEA-4(-) osteosarcoma cell dedifferentiation. Mechanistically, active mTORC1 is required to prevent a likely upregulation of the cell-cycle inhibitor p27 independently of p53 or Rb activation, which otherwise effectively drives the terminal differentiation of SSEA-4(-) osteosarcoma cells at the expense of dedifferentiation. Thus, mTORC1 is shown to critically regulate the retention of tumorigenicity versus differentiation in discrete differentiation phases in SSEA-4(+) TICs and their progeny.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bone Neoplasms / drug therapy
  • Bone Neoplasms / genetics
  • Bone Neoplasms / metabolism*
  • Bone Neoplasms / mortality
  • Bone Neoplasms / pathology*
  • Cell Cycle / genetics
  • Cell Dedifferentiation
  • Cell Transformation, Neoplastic / genetics
  • Cell Transformation, Neoplastic / metabolism*
  • Disease Models, Animal
  • Disease Progression
  • Epithelial-Mesenchymal Transition / genetics
  • Female
  • Heterografts
  • Humans
  • Mechanistic Target of Rapamycin Complex 1
  • Multiprotein Complexes / genetics
  • Multiprotein Complexes / metabolism*
  • Neoplasm Grading
  • Osteosarcoma / drug therapy
  • Osteosarcoma / genetics
  • Osteosarcoma / metabolism*
  • Osteosarcoma / mortality
  • Osteosarcoma / pathology*
  • Prognosis
  • Retinoblastoma Protein / genetics
  • Retinoblastoma Protein / metabolism
  • Stage-Specific Embryonic Antigens / genetics
  • Stage-Specific Embryonic Antigens / metabolism*
  • TOR Serine-Threonine Kinases / genetics
  • TOR Serine-Threonine Kinases / metabolism*
  • Tumor Suppressor Protein p53 / genetics
  • Tumor Suppressor Protein p53 / metabolism

Substances

  • Multiprotein Complexes
  • Retinoblastoma Protein
  • Stage-Specific Embryonic Antigens
  • Tumor Suppressor Protein p53
  • stage-specific embryonic antigen-4
  • Mechanistic Target of Rapamycin Complex 1
  • TOR Serine-Threonine Kinases